TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC announced the results of its 2025 Annual General Meeting, where five out of six resolutions were passed by shareholders. The special resolution, requiring a 75% approval, was not passed. This outcome reflects shareholder support for most of the company’s current strategies and leadership, although the failure of the special resolution may indicate some reservations among stakeholders regarding certain strategic directions.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with its lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
Average Trading Volume: 2,935,726
Technical Sentiment Signal: Hold
Current Market Cap: £12.29M
Learn more about IMM stock on TipRanks’ Stock Analysis page.